Efficacy evaluation of the numerical control liquid management system combined with blood gas monitoring in patients undergoing hysteroscopic surgery for benign uterine lesions.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600129444

Enrollment

Unknown

Registered

2026-08-05

Start date

2027-01-01

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Operative Hysteroscopy Intravascular Absorption (OHIA) Syndrome

Interventions

Exposome group (The percentage of the difference between the inflow and outflow of uterine distension fluid relative to the estimated effective circulating blood volume is greater than or equal to 30%

Control group (The percentage of the difference between the inflow and outflow of uterine distension fluid relative to the estimated effective circulating blood volume is less than 30%.):None

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Female patients, aged in accordance with clinical criteria for hysteroscopic surgery for benign uterine lesions. 2. Surgical conditions: Planned to undergo corresponding therapeutic hysteroscopic surgery in the central operating room of Fuxing Hospital. 3. Age between 18 and 50 years old (inclusive). 4. American Society of Anesthesiologists (ASA) physical status classification of Grade I or II, able to tolerate general anesthesia and surgery. 5. Informed consent: The patient understands the research purpose, procedures, and potential risks, voluntarily participates in this study, and has signed a written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Previous history of severe dysfunction of vital organs such as the heart, liver, and kidneys, or other underlying diseases affecting perioperative safety. 2. Previous definitive diagnosis of OHIA syndrome or related similar diseases. 3. Presence of severe cognitive impairment, mental disorders, or language communication barriers that may affect follow-up or compliance. 4. Patients unable to accurately measure the difference in uterine distension fluid input and output or estimate effective circulating blood volume. 5. Those who refuse follow-up or have not signed the informed consent form. 6. Patients who are preparing for pregnancy, during pregnancy, or within the lactation period are not included in this study.

Design outcomes

Primary

Measure	Time frame
Oxygenation index;	—

Secondary

Measure	Time frame
Arterial blood gas analysis base excess (BE) value;Blood gas analysis pH value;Arterial blood gas analysis--Lactic acid;	—

Countries

China

Contacts

Public ContactSun Jian

Fuxing Hospital Capital Medical University

jamessun625@hotmail.com+86 10 88062240

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026